Pull to refresh
Logo
What Changed
Following Why Sign Up
Aroa Biosurgery trial shows Symphony heals diabetic foot ulcers faster

Aroa Biosurgery trial shows Symphony heals diabetic foot ulcers faster

New Capabilities

Randomized controlled trial finds 55% closure rate at 12 weeks, 7.8 days faster healing

October 11th, 2026: Aroa holds investor call on Symphony trial

Overview

Updated Oct 26

Aroa Biosurgery published results from a randomized controlled trial showing its Symphony wound product heals diabetic foot ulcers faster than standard care. In the company's headline analysis, 55% of ulcers closed within 12 weeks with Symphony, versus 35% with standard care alone. The study appeared in the International Wound Journal.

Medicare has paid a flat $127.14 per square centimeter for these products in outpatient settings since January 1, 2026, replacing a percentage-of-price model. A July 2026 proposed rule would keep that rate for 2027, and it is not final. Aroa's chief executive said on an October 11 investor call that the trial gives physicians and payers the evidence they want.

Why it matters

With Medicare tightening reimbursement for wound products, this trial data could decide whether Symphony gets covered and sold in the US.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

55%
12-week closure rate with Symphony
55% of diabetic foot ulcers closed within 12 weeks with Symphony plus standard care, versus 35% with standard care alone (p=0.039).
7.8 days
Faster mean healing time
Mean time to closure was 65.4 days with Symphony versus 73.2 days with standard care (p=0.041).
143
Patients enrolled
Prospective multicenter trial across 10 US sites treating Wagner Grade 1 or 2 diabetic foot ulcers.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

David G. Armstrong
David G. Armstrong
Diabetic limb-preservation researcher
Active

Organizations Involved

Aroa Biosurgery Limited
Aroa Biosurgery Limited
Medical device company
Listed on ASX, commercializing Symphony in the US

New Zealand-based soft tissue regeneration company that developed Symphony.
Symphony
Symphony
Medical device / CAMP
FDA-cleared, now with Level I trial evidence

Aroa's wound dressing combining AROA ECM with high molecular weight hyaluronic acid.
Centers for Medicare & Medicaid Services
Centers for Medicare & Medicaid Services
Federal agency
Set a flat $127.14 per square centimeter rate from January 1, 2026; proposed keeping it for 2027

US agency that administers Medicare, which reclassified advanced wound products.

Timeline

June 2020 October 2026

8 events Latest: October 11th, 2026 · 1 month ago
Tap a bar to jump to that date

  1. Aroa holds investor call on Symphony trial

    Latest Market

    Chief executive Brian Ward and chief scientific officer Barnaby May presented the trial to investors. Management said the data should help with clinician adoption and US payer discussions.

  2. Bell Potter says Symphony potential not priced in

    Market

    Broker Bell Potter issued a research note saying Aroa's shares fail to reflect Symphony's commercial potential now that the product has Level I clinical evidence for US reimbursement.

  3. RCT results published

    Publication

    Results published in International Wound Journal show 55% closure rate at 12 weeks.

  4. CMS proposes keeping 2026 flat rate for 2027

    Regulatory

    CMS proposed keeping its $127.14 per square centimeter rate for skin substitutes in outpatient settings for 2027. The proposal is not final.

  5. Medicare reclassifies wound products

    Regulatory

    Medicare reclassifies most advanced wound products, tightening reimbursement criteria.

  6. Trial completes

    Trial

    Trial completes with 143 patients treated for up to 12 weeks.

  7. Randomized controlled trial begins

    Trial

    Prospective multicenter RCT of Symphony begins across 10 US sites.

  8. Symphony receives FDA clearance

    Regulatory

    Symphony receives FDA 510(k) clearance for wound treatment.

Scenarios

1

Symphony sales climb as RCT data wins formulary placements

Likely Resolves by Q2 2027

Discussed by: Bell Potter analyst, Clinical Trial Vanguard

Aroa's sales teams use the published RCT to win hospital formulary placements and payer coverage. Medicare's 2026 reclassification rewards controlled evidence, and Symphony now has it. Quarterly revenue reports show Symphony sales growing.

2

Rivals publish RCT data, eroding Symphony's edge

Possible Resolves by End of 2027

Discussed by: Industry analysts

Competing CAMP manufacturers respond with their own randomized trials, narrowing Symphony's differentiation. The market becomes crowded with Level I evidence, and pricing pressure returns.

3

Evidence fails to convert; Symphony sales stay flat

Unlikely Resolves by End of 2027

Discussed by: Kalkine, market observers

The RCT data is necessary but not sufficient. Hospital formularies move slowly, and Medicare's new payment framework still limits adoption. Symphony sales remain flat despite the evidence.

4

Aroa shares re-rate as Symphony evidence converts to sales

Likely Resolves by Q1 2027

Discussed by: Bell Potter, NBR, BusinessDesk

Bell Potter's research note says Aroa's shares do not reflect Symphony's commercial potential now that the product has Level I evidence. The broker expects the data to strengthen Aroa's hand with US reimbursement agencies and private payers in a wound-care market worth about US$1 billion.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

May 2012

TAVR coverage decision (2012)

CMS issued a national coverage determination for transcatheter aortic valve replacement (TAVR), covering the procedure for patients too frail for open surgery. The decision rested on data from the PARTNER trial, a randomized controlled study.

Then

TAVR adoption accelerated after coverage was secured.

Now

Set a precedent that Medicare would cover new devices when backed by randomized trial evidence.

Why this matters now

Shows how RCT data can unlock Medicare coverage for a new medical technology, the same mechanism Symphony is now pursuing.

2003-2004

Drug-eluting stents (2003-2004)

Drug-eluting stents entered the US market with clinical trial evidence showing they reduced restenosis compared with bare metal stents. The evidence drove rapid adoption and reimbursement.

Then

Drug-eluting stents quickly replaced bare metal stents as the standard of care.

Now

Demonstrated that controlled clinical evidence can accelerate adoption of a new device category.

Why this matters now

Illustrates how strong clinical evidence can shift an entire market, the outcome Aroa hopes for with Symphony.

Sources

(11)
+5
PRNewswire Clinical Trial Vanguard Kalkine NBR ClinicalTrials.gov ASX BusinessDesk Wound Care Weekly AROA EarningsAPI Quartr